Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Aurora Flight Sciences announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company the prime contract for Phase 2 of the Agency’s Vertical Takeoff and Landing Experimental Plane (VTOL X-Plane) program.
VTOL X-Plane seeks to develop a technology demonstrator that could:
• Achieve a top sustained flight speed of 300 kt-400 kt
• Raise aircraft hover efficiency from 60 percent to at least 75 percent
• Present a more favorable cruise lift-to-drag ratio of at least 10, up from 5-6
• Carry a useful load of at least 40 percent of the vehicle’s projected gross weight of 10,000-12,000 pounds
The Aurora team’s design for its unmanned aircraft, named LightningStrike, seeks to provide an approximately 50-percent increase in speed over existing VTOL aircraft designed for comparable mission applications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7617851-aurora-flight-sciences-vtol-xplane-darpa/
USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
University of St. Augustine for Health Sciences (USAHS), a leading graduate institution that emphasizes health and rehabilitative sciences education through innovative classroom education, is pleased to announce the installation of SafeGait 360° Balance and Mobility Trainer® on its Austin, Texas campus. The device, which was designed in collaboration with experts in physical therapy (PT) and occupational therapy (OT), works to mitigate the risk of injury from falls, protecting both the patient and therapist. In addition, SafeGait 360°’s dynamic fall protection (DFP) distinguishes between a patient’s intentional downward movement and when a patient is actually falling, which allows therapists to easily modify fall protection sensitivity to accommodate and challenge patients at varying stages of independence.
USAHS is one of the first higher education institutions in the nation to install this innovative body-weight support and fall protection system. In addition to conducting ground breaking research with patients and students, faculty members with extensive experience in body-weight treatments aim to open a clinic which will provide new treatment options to patients in the Austin community, and will begin seeing patients in October of this year.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743851-usahs-safegait-360-physical-therapy/
http://visalusshakes.com Actress and
fashion designer, LisaRaye McCoy, has been struggling with her lower
back which in turn has greatly limited her ability to move freely
without pain. After a visit to her Chiropractor, LisaRaye gets approval
to get back out there and start her pole dancing training. Watch as
LisaRaye overcomes her back issue, starts her mastery of pole dancing
and works her way to toward her ViSalus 90-Day Challenge Goal!
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to maintain, ScienceCloud improves operational excellence in globally networked research, significantly reducing IT cost and effort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65595-sciencecloud-software-by-accelrys-advances-collaborative-drug-discovery
The Healthy Home, a new book containing simple solutions for making your home healthier, was today released through Vanguard Publishing. Written by award-winning microbiologist Dr. Myron Wentz and USANA Health Sciences CEO Dave Wentz, The Healthy Home tackles everyday problems from chemicals in our household products to contaminants in our food and more. The authors will be traveling across North America on The Healthy Home Book Tour from March 25 to April 21, 2011 and are proud to donate all their proceeds to Children’s Hunger Fund (CHF), a nonprofit organization distributing food and other vital resources to children from impoverished communities worldwide.
To view Multimedia News RFelease, go to http://multivu.prnewswire.com/mnr/usana-healthy-home-launch/49154/
From promising methods for diagnosing Alzheimer's and modern implant technology to high stability concrete, an efficient biomass furnace and water purification with ultraviolet light the winners of the European Inventor Award 2011 cover a wide spectrum of pioneering technological solutions and are a testament to Europe's innovative capacity. The European Patent Office (EPO), in cooperation with the Hungarian EU Council Presidency and the European Commission, awarded Europe's most prestigious innovation prize in five categories at a ceremony at the Academy of Sciences in Budapest today.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/epo/48919/
The Dan David Prize award ceremony took place yesterday at Tel Aviv University, in the presence of Prof. Joseph Klafter, President of Tel Aviv University and Chairman of the Dan David Prize Board, Prof. Ruth Arnon, President of the Israel Academy of Sciences, members of the David family, the 2012 Dan David Prize laureates, foreign ambassadors, and prominent academic and business figures from Israel and abroad.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56538-dandavidprize
Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York, NY. Victor Ambros, Ph.D., of the University of Massachusetts Medical School, and Gary Ruvkun, Ph.D., of Massachusetts General Hospital and Harvard Medical School, received the award for their collaborative discovery of microRNAs (miRNAs) as central regulators of gene expression and development, and will share a $100,000 prize.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58019-johnson-and-johnson-jnj-2012-dr-paul-janssen-award-for-biomedical-research
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
